Roivant Sciences Ltd. - 12 Dec 2025 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: IMVT
Reported as of: 12 Dec 2025
Net transaction value: +$349,999,986
SEC form: 4
Accepted by SEC: 12 Dec 2025, 17:17:21 UTC
Prior SEC filing: 15 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Keyur Parekh, as Authorized Signatory

Key filing fact

Roivant Sciences Ltd. filed Form 4 for Immunovant, Inc. (IMVT) on 12 Dec 2025.

Key facts

This page summarizes Roivant Sciences Ltd.'s Form 4 filing for Immunovant, Inc. (IMVT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Dec 2025, 17:17.

Change

Previous filing in this sequence was filed on 15 Jan 2025.
Current net transaction value: +$349,999,986.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001635088 Primary reporting owner

Roivant Sciences Ltd.

Relationship: Director, 10%+ Owner
Address: 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM
Signature: /s/ Keyur Parekh, as Authorized Signatory
Signature date: 12 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMVT transaction

Common Stock, $0.0001 par value per share

Purchase

Transaction value: $349,999,986
Shares: +16,666,666
Change %: +17%
Price: $21.00
Shares after: 113,317,007
Date: 12 Dec 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

The Reporting Person is deemed to be a "director by deputization" of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934 by virtue of the fact that Frank M. Torti, M.D. (who serves as President & Vant Chair of Roivant Sciences, Inc. ("RSI"), a subsidiary of the Reporting Person), Eric Venker, M.D., Pharm.D. (who serves as President of RSI) and Andrew Fromkin (who serves as the Vant Portfolio Operating Partner for RSI) each currently serve on the board of directors of the Issuer on behalf of the Reporting Person.